Table 3. The association of miR-630 and Bcl-2 expression levels with the response to cisplatin-based therapy in lung cancer patients.

		The response to cisplatin therapy
Variables	Patient No.	Unfavorable (%)	Favorable (%)	P
miR-630
Low	42	28 (66.7)	14 (33.3)	0.003
High	32	10 (31.3)	22 (68.8)
Bcl-2
Low	31	9 (29.0)	22 (71.0)	0.001
High	43	29 (67.4)	14 (32.6)

Complete response (CR): a complete disappearance of all the tumors; partial response (PR): a decrease in size or number of the tumor lesions by 50% or more; progressive disease (PD): at least 25% increase in size or number of the tumor lesions; and stable disease (SD): neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease. Therefore, the favorable response (CR and PR) is the decrease of tumor size at least 50% or more.